Main content 1 Menu 2 Search 3 Footer 4
+A
A
-A
High contrast
HOME JOURNAL CRITERIA NETWORK HELP ABOUT

Current criteria:

Regional:

WPRlM journal selection criteria(2023)

Minimum standards for the suspension and removal of WPRIM approved journals

Countries journal selection criteria:

Philippines

Submit your journal information>

Contact NJSCs>

Laboratory Medicine Online

2011  to  Present  ISSN: 2093-6338

Articles

About

Year of publication

Save Email

Sort by

Best match
Relevance
PubYear
JournalTitle

DISPLAY OPTIONS

Format:

Per page:

Save citations to file

Selection:

Format:

Create file Cancel

Email citations

To:

Please check your email address first!

Selection:

Format:

Send email Cancel

410

results

page

of 41

1

Cite

Cite

Copy

Share

Share

Copy

Neutrophilic Leukemoid Reaction Associated with Malignancy Initially Suspected as Chronic Neutrophilic Leukemia.

Min Kyung SO ; Sholhui PARK ; Yeung Chul MUN ; Chu Myong SEONG ; Hee Jin HUH ; Jungwon HUH

Laboratory Medicine Online.2017;7(4):206-210. doi:10.3343/lmo.2017.7.4.206

Although neutrophilia can manifest from various causes, it is important to be able to distinguish chronic neutrophilic leukemia (CNL) from neutrophilic leukemoid reactions (NLR). In this paper, we describe four cases of leukocytosis with neutrophilia, including one case of CNL with a T618I mutation in colony stimulating factor 3 receptor (CSF3R) and three cases of NLR associated with malignancy or sepsis, which were initially suspected as CNL. Of the three NLR cases, one was associated with ovarian cancer, one with monoclonal gammopathy of undetermined significance and one with multiple myeloma with sepsis. This study demonstrated that confirming the clonality of myeloid cells with CSF3R T618I could contribute to making an accurate differential diagnosis between CNL and NLR in patients with solid cancers or plasma cell neoplasms caused by paraneoplastic syndromes and/or infection.
Colony-Stimulating Factors ; Diagnosis, Differential ; Humans ; Leukemia, Neutrophilic, Chronic* ; Leukemoid Reaction* ; Leukocytosis ; Monoclonal Gammopathy of Undetermined Significance ; Multiple Myeloma ; Myeloid Cells ; Neoplasms, Plasma Cell ; Neutrophils* ; Ovarian Neoplasms ; Paraneoplastic Syndromes ; Sepsis

Colony-Stimulating Factors ; Diagnosis, Differential ; Humans ; Leukemia, Neutrophilic, Chronic* ; Leukemoid Reaction* ; Leukocytosis ; Monoclonal Gammopathy of Undetermined Significance ; Multiple Myeloma ; Myeloid Cells ; Neoplasms, Plasma Cell ; Neutrophils* ; Ovarian Neoplasms ; Paraneoplastic Syndromes ; Sepsis

2

Cite

Cite

Copy

Share

Share

Copy

Five Cases of the Gram Variable Bacterium Paenibacillus urinalis Isolated from Clinical Specimens and its Clinical Significance.

Hyunjung GU ; Young Jin KIM ; Jiyun RYU ; Sun Young CHO ; Hee Joo LEE

Laboratory Medicine Online.2017;7(4):201-205. doi:10.3343/lmo.2017.7.4.201

Paenibacillus urinalis was first isolated from the urine of a woman in 2008, and was reported to be a contaminant. Here, we report 5 cases of P. urinalis isolated over 5 months at a tertiary hospital. Using an API kit, 4 cases were classified as Cellulomonas species. Owing to the low reliability of API kit results and Gram stain results indicating gram variable bacilli for few specimens, MALDI-TOF MS and 16S rRNA gene sequencing were performed for identification. The last case showed Gram variable bacilli, and therefore, based on previous experience, 16S rRNA gene base sequence analysis was carried out without an additional API kit. All isolated strains were confirmed to be P. urinalis, and were judged to be contaminants. As for Gram variable bacteria, the use of current biochemical identification systems may lead to misidentification as other bacteria, which may cause unnecessary or improper use of antibiotics. Moreover, whereas most of the Paenibacillus species are reported to be contaminants, some of them are being reported as sources of infection. Therefore, more accurate identification will be necessary in the future. Accordingly, it is expected that accurate identification of this genus will help clinical physicians make decisions regarding appropriate treatment and use of antibiotics.
Anti-Bacterial Agents ; Bacteria ; Base Sequence ; Cellulomonas ; Female ; Genes, rRNA ; Humans ; Paenibacillus* ; Tertiary Care Centers

Anti-Bacterial Agents ; Bacteria ; Base Sequence ; Cellulomonas ; Female ; Genes, rRNA ; Humans ; Paenibacillus* ; Tertiary Care Centers

3

Cite

Cite

Copy

Share

Share

Copy

A Case of Acute Promyelocytic Leukemia with Co-existence of BCR-ABL1 and PML-RARA Rearrangements Detected by PCR.

Gyu Dae AN ; Hyeon Ho LIM ; Kwang Sook WOO ; Kyeong Hee KIM ; Jeong Man KIM ; Sung Hyun KIM ; Jin Yeong HAN

Laboratory Medicine Online.2017;7(4):196-200. doi:10.3343/lmo.2017.7.4.196

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) characterized by PML-RARA fusion and specific morphology. The BCR-ABL1 rearrangement is mainly observed in patients with chronic myeloid leukiemia (CML). However, it is also found in patients with acute lymphoblastic leukemia (ALL) and in a few patients with AML. However, it is very rarely observed in patients with APL. Here, we report a case of APL with t(15;17) and co-existence of PML-RARA and BCR-ABL1. Further study with more cases is warranted to find the right treatment and prognostic significance.
Humans ; Leukemia, Myeloid, Acute ; Leukemia, Promyelocytic, Acute* ; Polymerase Chain Reaction* ; Precursor Cell Lymphoblastic Leukemia-Lymphoma

Humans ; Leukemia, Myeloid, Acute ; Leukemia, Promyelocytic, Acute* ; Polymerase Chain Reaction* ; Precursor Cell Lymphoblastic Leukemia-Lymphoma

4

Cite

Cite

Copy

Share

Share

Copy

National Survey on Biosafety in Clinical Tuberculosis Laboratories in Korea.

Chang Ki KIM ; Hyukmin LEE ; Dongeun YONG ; Young Ah KIM

Laboratory Medicine Online.2017;7(4):189-195. doi:10.3343/lmo.2017.7.4.189

BACKGROUND: Workers in the microbiology laboratories are continuously exposed to the risk of laboratory-associated infections. Tuberculosis (TB) is a frequent laboratory-acquired infection owing to production of cough-generated aerosols with ease and high infectivity of Mycobacterium tuberculosis. This study aims to investigate the current situation of biosafety in Korean TB laboratories. METHODS: We conducted a nationwide survey of laboratories in hospitals conducting TB tests using questionnaires about their facility and management standards. RESULTS: We analyzed data from 52 hospitals nationwide that have a capacity of 100–2,000 beds, of which only two laboratories conduct high risk drug-susceptibility testing on cultured isolates among other test items, whereas six laboratories perform only direct sputum-smear microscopy. The remaining laboratories performed moderate-risk activities/tests, like sample processing for culture. In the majority of these laboratories, there are laboratory medicine specialists who are fully in charge of health checkup programs for laboratorians. The facility and management standards vary widely according to the size of the hospital and risk of TB tests. CONCLUSIONS: Our survey results about the current situation of TB laboratories could be useful as baseline data for preparing biosafety guidelines for all TB laboratories in Korea.
Aerosols ; Korea* ; Microscopy ; Mycobacterium tuberculosis ; Specialization ; Tuberculosis*

Aerosols ; Korea* ; Microscopy ; Mycobacterium tuberculosis ; Specialization ; Tuberculosis*

5

Cite

Cite

Copy

Share

Share

Copy

Evaluation of Cobas b 101 HbA1c Analyzer Performance for Point-of-Care Testing.

Hui Jin YU ; Sangeun LIM ; Min Jung KWON ; Hee Yeon WOO ; Hyosoon PARK

Laboratory Medicine Online.2017;7(4):182-188. doi:10.3343/lmo.2017.7.4.182

BACKGROUND: The use of point-of-care (POC) devices for evaluating HbA1c is increasing; accordingly, comparisons between these devices and central laboratory methods are important. In the present study, we evaluated the analytical performance of the cobas b 101 analyzer for POC HbA1c testing. METHODS: The analytical quality of the cobas b 101 system was assessed based on repeatability, within-laboratory precision, linearity, and lot-to-lot reproducibility. Two specimen types, i.e., EDTA whole blood and capillary blood, were examined using the cobas b 101 system and the Variant II Turbo instrument. RESULTS: The coefficient of variation for within laboratory precision was 5.22% for a normal HbA1c level and 2.56% for a higher HbA1c level. The method showed good linearity, with a coefficient of correlation of 0.990. In a comparison of two different HbA1c disk lots, a strong correlation (r=0.986) and a mean %difference of −2.9% were observed. The cobas b 101 results using EDTA whole blood were strongly correlated with the Variant II Turbo results (r=0.958), with a mean %difference of 0.8%; the cobas b 101 results using capillary blood were strongly correlated with the Variant II Turbo results, using EDTA whole blood (r=0.976), with a mean %difference of 2.0%. A comparison between HbA1c levels in EDTA whole blood and capillary blood obtained using the cobas b 101 showed a strong correlation (r=0.985) and a mean %difference of 1.3%. CONCLUSIONS: The cobas b 101 analyzer is convenient for the measurement of HbA1c levels for diabetes management.
Capillaries ; Edetic Acid ; Methods ; Point-of-Care Systems* ; Point-of-Care Testing*

Capillaries ; Edetic Acid ; Methods ; Point-of-Care Systems* ; Point-of-Care Testing*

6

Cite

Cite

Copy

Share

Share

Copy

Establishing Reference Intervals for Soluble ST2 Assay in a Korean Population.

Mikyoung PARK ; Misuk JI ; Hanah KIM ; Hee Won MOON ; Mina HUR ; Yeo Min YUN

Laboratory Medicine Online.2017;7(4):176-181. doi:10.3343/lmo.2017.7.4.176

BACKGROUND: Soluble ST2 (sST2) has emerged as a biomarker of heart failure. Previous studies indicated 35 ng/mL of sST2 as the clinically prognostic cut-off value. This study aims to establish reference intervals in a Korean population using an sST2 assay and to evaluate the applicability of the cut-off value. METHODS: From March to May 2014, sST2 levels were assayed in serum samples of 255 cardio-healthy Koreans (128 men and 127 women) using the Presage ST2 ELISA kit (Critical Diagnostics, USA). The reference interval for sST2 was defined using the nonparametric percentile method according to the CLSI EP28-A3c guideline. RESULTS: The median sST2 concentrations were 23.8 ng/mL (interquartile range (IQR), 19.0-28.7), 26.6 ng/mL (IQR, 21.0-30.9), and 21.9 ng/mL (IQR, 17.3-26.5) for the entire cohort, men, and women, respectively. sST2 levels were significantly higher in men than in women (P<0.0001). The 97.5th percentile upper reference limits for sST2 were 43.8 ng/mL, 49.6 ng/mL, and 35.4 ng/mL for the cohort, men, and women, respectively. Gender-specific upper reference limits were similar to limits reported by other studies. CONCLUSIONS: We suggest that gender-specific reference intervals should be used for the Korean population, as application of a single cut-off value of 35 ng/mL may be overcautious of the possibility of false positivity, especially in men.
Cohort Studies ; Enzyme-Linked Immunosorbent Assay ; Female ; Heart Failure ; Humans ; Male ; Methods

Cohort Studies ; Enzyme-Linked Immunosorbent Assay ; Female ; Heart Failure ; Humans ; Male ; Methods

7

Cite

Cite

Copy

Share

Share

Copy

Evaluation of the Automated Blood Bank Systems IH-500 and VISION Max for ABO-RhD Blood Typing and Unexpected Antibody Screening.

Yumi PARK ; Seon Young KIM ; Sun Hoe KOO ; Jinsook LIM ; Ji Myung KIM ; Young Ae LIM ; Gye Cheol KWON

Laboratory Medicine Online.2017;7(4):170-175. doi:10.3343/lmo.2017.7.4.170

BACKGROUND: The use of automated systems for pre-transfusion tests is increasing in an attempt to reduce workload and the impact of human errors in blood banks. We evaluated the clinical performance of the automated blood bank systems IH-500 (Bio-Rad Laboratories, Switzerland) and VISION Max (Ortho-Clinical Diagnostics, USA) for ABO-RhD blood typing and unexpected antibody screening. METHODS: ABO-RhD blood typing was performed for 410 samples, and antibody screening was performed for 332 samples, including 15 antibody-positive samples. The results obtained from the two automated instruments were compared with those obtained using manual methods for ABO-RhD blood typing and a semiautomated method (DiaMed-ID system) for antibody screening. Additionally, both instruments were evaluated in terms of concordance rates, sensitivity, and carryover. RESULTS: The concordance rate of the ABO-RhD blood typing results between the manual methods and the two automated instruments was 100%. For antibody screening tests, the concordance rates between the semiautomated method (DiaMed-ID system) and the automated methods were 100% and 99.7% for the IH-500 and VISION Max instruments, respectively. The sole discrepant result was obtained for a sample identified as antibody-positive only on the VISION Max; the antibody was identified as anti-Le(a). The overall sensitivity of the two automated instruments was the same as or higher than that of the semiautomated method. Carryover was not observed in antibody screening. CONCLUSIONS: The IH-500 and VISION Max instruments showed reliable results for ABO-RhD blood typing and unexpected antibody screening, and can be used clinically, with confidence, for pre-transfusion tests in the blood bank.
Automation ; Blood Banks* ; Blood Grouping and Crossmatching* ; Humans ; Mass Screening* ; Methods

Automation ; Blood Banks* ; Blood Grouping and Crossmatching* ; Humans ; Mass Screening* ; Methods

8

Cite

Cite

Copy

Share

Share

Copy

Evaluation of the Automated Immunohematology Analyzer DAYMATE M.

Jaeeun YOO ; Hain YU ; Hyunyu CHOI ; Gyoo Whung LEE ; Young Sun SONG ; Seungok LEE ; Dong Wook JEKARL ; Yonggoo KIM

Laboratory Medicine Online.2017;7(4):163-169. doi:10.3343/lmo.2017.7.4.163

BACKGROUND: An automated immunohematology analyzer, DAYMATE M (DAY Medical, Switzerland), has been recently developed. The potential of this analyzer to improve test results has been evaluated. METHODS: A total of 300 blood samples from Seoul St. Mary's hospital and Incheon St. Mary's hospital were tested for ABO and RhD typing. In addition, 336 antibody screening test (AST) samples and 82 patients treated with hematopoietic stem cell transplantation (HSCT) were included. AST results by DAYMATE M were compared with those obtained by a manual method using DS-Screening II (Bio-Rad Laboratories, Switzerland) and red blood cells from Selectogen (Ortho-Clinical diagnostics Inc., USA). RESULTS: Of the 300 patients enrolled, 87, 73, 79, and 61 had type A, B, O, and AB blood, respectively. The concordance rate was 99.9% for cell typing and 97.0% for serum typing. One discordant case was classified as type B instead of AB, and six discordant serum-typing cases were type A, but classified as type AB. Among the 336 AST samples, the concordance rate was 93.2%. From 136 positive cases, six were discordant. Within the 82 HSCT-treated patients, the concordance rate for ABO blood typing was 92.2%. Among the six discordant cases, DAYMATE M typed four cases as donor type where the standard method typed them as the recipient blood type. CONCLUSIONS: The DAYMATE M automated immunohematology analyzer performs reliably for ABO and RhD typing, as well as for ASTs and on samples from patients treated with HSCT.
Blood Grouping and Crossmatching ; Erythrocytes ; Hematopoietic Stem Cell Transplantation ; Humans ; Incheon ; Mass Screening ; Methods ; Seoul ; Tissue Donors

Blood Grouping and Crossmatching ; Erythrocytes ; Hematopoietic Stem Cell Transplantation ; Humans ; Incheon ; Mass Screening ; Methods ; Seoul ; Tissue Donors

9

Cite

Cite

Copy

Share

Share

Copy

Evaluation of the Verigene Warfarin Metabolism Nucleic Acid Test Kit for the Rapid Detection of CYP2C9 and VKORC1 Polymorphisms.

Hyeyoung LEE ; Jiyeon KIM ; Gun Dong LEE ; Joonhong PARK ; Hyojin CHAE ; Myungshin KIM ; Yonggoo KIM ; Yong Seog OH

Laboratory Medicine Online.2014;4(4):198-202. doi:10.3343/lmo.2014.4.4.198

BACKGROUND: Warfarin is a widely used oral agent for anticoagulation therapy. Warfarin has a narrow therapeutic index and a wide variation in the interindividual therapeutic dosage. Recently, genotypes of CYP2C9 and VKORC1 have been found to account for 30-40% of the warfarin dosing variability, and a variety of commercial genotyping assays are being introduced. In this study, we evaluated the Verigene Warfarin Metabolism Nucleic Acid test (Verigene Warfarin assay; Nanosphere, USA) for its accuracy and clinical utility in genotyping CYP2C9*2, CYP2C9*3, and VKORC1 1173C>T. METHODS: We compared the Verigene Warfarin assay with direct sequencing for accuracy in determining the genotypes of CYP2C9*2, CYP2C9*3, and VKORC1 1173C>T using 50 patient samples and 3 commercial DNA samples with known genotypes. The method was also evaluated for turn-around time, hands-on time, and feasibility. RESULTS: The Verigene Warfarin assay demonstrated 100% accuracy for identifying CYP2C9*2, CYP2C9*3, and VKORC1 1173C>T. The turn-around time and hands-on time were 3 hr and 2 min, respectively. The no-call error rate at first attempt was estimated to be 2%. CONCLUSIONS: The Verigene Warfarin assay provides rapid and accurate genotype results. Considering there are only a few steps requiring manual intervention, it would be feasible to implement this assay even in clinical laboratories that lack considerable expertise in molecular diagnostics.
DNA ; Genotype ; Humans ; Metabolism* ; Nanospheres ; Pathology, Molecular ; Warfarin*

DNA ; Genotype ; Humans ; Metabolism* ; Nanospheres ; Pathology, Molecular ; Warfarin*

10

Cite

Cite

Copy

Share

Share

Copy

Significance of Neutrophil Gelatinase-Associated Lipocalin Level as an Acute-Phase Reactant in Patients with Systemic Inflammatory Response Syndrome.

Young Su JE ; Jong Weon CHOI ; Seung Baik HAN ; Yeonsook MOON ; Ji Eun LEE

Laboratory Medicine Online.2014;4(4):191-197. doi:10.3343/lmo.2014.4.4.191

BACKGROUND: We investigated the significance of plasma neutrophil gelatinase-associated lipocalin (pNGAL) level as an acute-phase reactant and an index for an increase in serum creatinine (sCr) level in patients with inflammatory diseases. METHODS: A total of 63 patients with systemic inflammatory response syndrome (SIRS) and 149 without SIRS were evaluated, and pNGAL level was determined using a fluorescence immunoassay. sCr levels were measured daily during three days, and the difference between the initial and follow-up sCr levels was defined as a delta sCr value. Serum albumin/sCr ratio (sACR) was calculated. High-sensitivity C-reactive protein (hsCRP) level was determined using a latex turbidometric method. RESULTS: The median pNGAL level in the SIRS group (154 ng/mL) was significantly higher than that in the non-SIRS (86 ng/mL) and control (62 ng/mL) groups (P<0.001, respectively). The area under the ROC curve (AUC) of pNGAL for diagnosing SIRS was 0.725 (95% CI, 0.664-0.781), which was not significantly different from that of hsCRP (0.749; 95% CI, 0.685-0.809; P=0.375). Multivariate regression analyses revealed that log-pNGAL was significantly associated with hsCRP (beta=0.546, P<0.001) and sACR (beta=0.351, P<0.001). The AUC of pNGAL for the positive delta sCr in 48-72 hr was 0.649 (95% CI, 0.542-0.746, P=0.023) in the SIRS group. CONCLUSIONS: pNGAL is comparable to hsCRP as an inflammation-related parameter, and its measurement may provide additional information for a potential increase in sCr during 48-72 hr in patients with SIRS.
Area Under Curve ; C-Reactive Protein ; Creatinine ; Fluorescence ; Follow-Up Studies ; Humans ; Immunoassay ; Latex ; Lipocalins* ; Neutrophils* ; Plasma ; ROC Curve ; Systemic Inflammatory Response Syndrome*

Area Under Curve ; C-Reactive Protein ; Creatinine ; Fluorescence ; Follow-Up Studies ; Humans ; Immunoassay ; Latex ; Lipocalins* ; Neutrophils* ; Plasma ; ROC Curve ; Systemic Inflammatory Response Syndrome*

Country

Republic of Korea

Publisher

Korean Society for Laboratory Medicine

ElectronicLinks

http://labmedonline.org/index.php

Editor-in-chief

Chulhun Chang

E-mail

kscp1@kams.or.kr

Abbreviation

Lab Med Online

Vernacular Journal Title

ISSN

2093-6338

EISSN

Year Approved

2012

Current Indexing Status

Currently Indexed

Start Year

2011

Description

Related Sites

WHO WPRO GIM

Help Accessibility
DCMS Web Policy
CJSS Privacy Policy

Powered by IMICAMS( 备案号: 11010502037788, 京ICP备10218182号-8)

Successfully copied to clipboard.